Holen Sie sich die Stockscreener-App
27.12
2.14%
-0.39
Schlusskurs vom Vortag:
$27.51
Offen:
$26.95
24-Stunden-Volumen:
7.74M
Relative Volume:
0.24
Marktkapitalisierung:
$6.27B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
51.94
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+6.83%
1M Leistung:
-1.79%
6M Leistung:
-27.38%
1J Leistung:
-50.81%
1-Tages-Spanne:
$25.71
$27.14
1-Wochen-Bereich:
$24.13
$28.39
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.11 | 6.37B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.01 | 47.96B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.715 | 38.49B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.93 | 32.02B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.31 | 22.92B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Most and least shorted mid- to mega-cap healthcare stocks at the end of May - Seeking Alpha
Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings - Yahoo Finance
Canaccord reiterates Hims & Hers stock Buy rating on peptide growth - Investing.com Canada
Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story - Yahoo Finance
Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap - simplywall.st
HIMS stock slips despite early eucalyptus buyout close: Analyst sees 10% downside on GLP-1 profit risks - MSN
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Hims & Hers Health Options Spot-On: On June 2nd, 101.18K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo
EXCLUSIVE: Sen. Jim Banks wants FDA and FTC to investigate whether Hims & Hers is undermining TrumpRx - Washington Reporter
HIMS: 2030 targets hinge on global expansion, AI-driven care, and integrated specialty growth - TradingView
Hims & Hers Expands With Eucalyptus Acquisition - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health, Inc. completed the acquisition of EUC Management Pty Ltd. - marketscreener.com
Leerink maintains Hims and Hers stock rating on acquisition timing - Investing.com
HIMS Expands Global Reach with Eucalyptus Acquisition - GuruFocus
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market - 01net
Hims & Hers Closes Eucalyptus Deal, Expands Global Platform - TipRanks
Hims & Hers Amends Revolving Credit Agreement With JPMorgan to Support Eucalyptus Deal - TradingView
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth Prospects - Yahoo Finance
Hims & Hers (NYSE: HIMS) expands with Eucalyptus deal and 2030 growth targets - Stock Titan
Hims & Hers completes acquisition of Eucalyptus in Australia - Investing.com Australia
Hims & Hers completes acquisition of Eucalyptus, enters Japan By Investing.com - Investing.com Australia
Press Release: Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany - Moomoo
Hims & Hers completes acquisition of Juniper parent Eucalyptus - Investing.com
Hims & Hers completes acquisition of Eucalyptus - Investing.com
Hims & Hers completes acquisition of Eucalyptus in Germany By Investing.com - Investing.com Canada
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform - HIMS Investor Relations
How We’re Reimagining The Future of Health for Hundreds of Millions of People - Hims & Hers Newsroom
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany - Eagle-Tribune
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform - standard-journal.com
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians - New Castle News
$Hims & Hers Health (HIMS.US)$ come on break that 31.5ish orange line so we can go up to upper green - Moomoo
LULU Settles With Wilson, HIMS and CHWY Value Picks - Gotrade
Is Hims & Hers Stock an Undervalued Stock to Buy? - The Motley Fool
Is Hims & Hers Stock an Undervalued Stock to Buy? - The Motley Fool
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - Stocktwits
Hims & Hers Health Options Spot-On: On June 1st, 185.47K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
$Hims & Hers Health (HIMS.US)$ - Moomoo
Lead Independent Director of Hims & Hers Health David Wells Buys 27% More Shares - simplywall.st
$Hims & Hers Health (HIMS.US)$ Not bad! About one year plus with HIMs and it never failed me. - Moomoo
$Hims & Hers Health (HIMS.US)$ that’s what I’m talking about $Hims & Hers Health (HIMS.US)$ 📈 - Moomoo
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health Stock (HIMS) Opinions on technical resistance levels - Quiver Quantitative
HIMS stock eyes breakout week: Eight new partners fuel push to build an all-in-one health platform - MSN
Hims & Hers Health, Inc. Registered Shs A Cert Deposito Arg Repr 0.25 Shs - TradingView
Net income of Hims & Hers Health, Inc. Registered Shs A Cert Deposito Arg Repr 0.25 Shs – BCBA:HIMSC - TradingView
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):